Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy

Shannon W. Finks, Toby C. Trujillo, Paul P. Dobesh

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Objective: To review clinical data on direct oral anticoagulants (DOACs) used in the acute treatment of venous thromboembolism (VTE) as well as practical considerations when using these products. Data Sources: Searches of PubMed and Google Scholar for VTE, deep vein thrombosis, pulmonary embolism, and relevant drug international nonproprietary names were conducted. Additional online searches were conducted for prescribing information. Study Selection and Data Extraction: Relevant articles on dabigatran, rivaroxaban, apixaban, and edoxaban for the management of VTE compared with oral vitamin K antagonists (VKAs; published between 1966 and December 2015) were reviewed and summarized, together with information on dosing, pharmacokinetics/pharmacodynamics, and drug-drug interactions. Data Synthesis: The DOACs have the potential to circumvent many of the disadvantages of VKAs. At a minimum, they greatly increase the available therapeutic options, thus providing a greater opportunity for clinicians to select a management option that best fits the needs of individual patients. Despite the significant advance that DOACs represent, they are not without risk and require careful consideration of a number of clinical issues to optimize safety and efficacy. Conclusions: The emergence of DOACs for the management of thromboembolic disorders represents a paradigm shift from oral VKAs. The DOACs provide similar efficacy and improved safety in selected patients as compared with VKAs. Clinicians treating VTE need to be familiar with the intricacies involved in using these agents, including the appropriate dose selection for the relevant indication, avoidance of drug-drug and drug-disease interactions, and consideration of dose adjustments in specific clinical situations, such as organ dysfunction.

Original languageEnglish (US)
Pages (from-to)486-501
Number of pages16
JournalAnnals of Pharmacotherapy
Issue number6
StatePublished - Jun 2016


  • apixaban
  • dabigatran
  • deep vein thrombosis
  • direct oral anticoagulants
  • edoxaban
  • pulmonary embolism
  • rivaroxaban
  • target-specific oral anticoagulants
  • venous thromboembolism

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy'. Together they form a unique fingerprint.

Cite this